News Releases - CSL
WEB4 days ago · CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...
News Releases - CSL
WEBApr 17, 2024 · Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
Global Newsroom | CSL
WEBAs we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the... Read more news from CSL Seqirus
News Releases | CSL
WEBDec 14, 2021 · Expands Leadership Positions and Diversifies CSL’s Business Model. The transaction expands CSL’s portfolio breadth with the addition of 10 commercialised products including Ferinject / Injectafer, Venofer, Veltassa, and soon Korsuva, adding leadership positions across multiple franchises.
News Releases | CSL
WEBSince our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in …
News Releases - CSL
WEBKING OF PRUSSIA, Pa., Feb. 26, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL's investigational first-in-class monoclonal antibody being developed as a …
News Releases - CSL
WEBFeb 7, 2022 · Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility will support the company’s growing R&D portfolio, with a focus on a self-amplifying messenger RNA (sa-mRNA) technology platform, the ...
New COVID-19 sa-mRNA Results from CSL and Arcturus …
WEBFeb 5, 2024 · New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster Study conducted by Meiji Seika Pharma in Japan
Annual Reports | Global Biotechnology Company | CSL - CSL Limited
WEBCSL's latest and archived Annual Reports. CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
Global Biotechnology Company | CSL
WEBCSL Behring is pleased to announce applications for the Prof Heimburger Award 2025 are now open for researchers in the areas of acquired and inherited bleeding disorders. Five grants of €25,000 are given each year to early-career researchers from all over the world.